Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma
暂无分享,去创建一个
Miguel Alaminos | Nazneen Rahman | Manel Esteller | Pablo Lapunzina | N. Rahman | M. Fraga | S. Ropero | F. Setién | M. Esteller | R. Losson | P. Lapunzina | N. Cheung | M. Berdasco | M. Alaminos | Mario F Fraga | Nai-Kong Cheung | Santiago Ropero | María Berdasco | Régine Losson | Fernando Setien
[1] P. Lapunzina. Risk of tumorigenesis in overgrowth syndromes: A comprehensive review , 2005, American journal of medical genetics. Part C, Seminars in medical genetics.
[2] W. Gerald,et al. Genomic medicine and neuroblastoma , 2003, Expert review of molecular diagnostics.
[3] Andrew P Feinberg,et al. The epigenetics of cancer etiology. , 2004, Seminars in cancer biology.
[4] N. Watanabe,et al. Identification of Genes Targeted by CpG Island Methylator Phenotype in Neuroblastomas, and Their Possible Integrative Involvement in Poor Prognosis , 2008, Oncology.
[5] V. Cormier-Daire,et al. Sotos syndrome , 2007, Orphanet journal of rare diseases.
[6] J. Cheng,et al. A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. , 2001, Blood.
[7] N. Rahman,et al. NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes. , 2003, American journal of human genetics.
[8] N. Rahman,et al. Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations. , 2005, American journal of human genetics.
[9] A. Feinberg,et al. The history of cancer epigenetics , 2004, Nature Reviews Cancer.
[10] Carla Oliveira,et al. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function , 2009, Nature Genetics.
[11] F. Westermann,et al. Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. , 2007, Cancer letters.
[12] W. Gerald,et al. Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. , 2003, Cancer research.
[13] N. Niikawa,et al. Molecular characterization of NSD1, a human homologue of the mouse Nsd1 gene. , 2001, Gene.
[14] Peter A. Jones,et al. Epigenetics in cancer. , 2010, Carcinogenesis.
[15] Danny Reinberg,et al. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. , 2004, Genes & development.
[16] P. Chambon,et al. Nizp1, a Novel Multitype Zinc Finger Protein That Interacts with the NSD1 Histone Lysine Methyltransferase through a Unique C2HR Motif , 2004, Molecular and Cellular Biology.
[17] N. Rahman. Mechanisms predisposing to childhood overgrowth and cancer. , 2005, Current opinion in genetics & development.
[18] K. Boon,et al. The MEIS1 oncogene is highly expressed in neuroblastoma and amplified in cell line IMR32. , 2001, Genomics.
[19] Dustin E. Schones,et al. High-Resolution Profiling of Histone Methylations in the Human Genome , 2007, Cell.
[20] J. Vonesch,et al. Two distinct nuclear receptor interaction domains in NSD1, a novel SET protein that exhibits characteristics of both corepressors and coactivators , 1998, The EMBO journal.
[21] Yi Zhang,et al. hDOT1L Links Histone Methylation to Leukemogenesis , 2005, Cell.
[22] G. Wang,et al. NUP98–NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis , 2007, Nature Cell Biology.
[23] M. Fraga,et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.
[24] Peter A. Jones,et al. The Epigenomics of Cancer , 2007, Cell.
[25] 黒滝 直弘. 私の論文から Haploinsufficiency of NSD1 causes Sotos syndrome , 2003 .
[26] Pierre Chambon,et al. NSD1 is essential for early post‐implantation development and has a catalytically active SET domain , 2003, The EMBO journal.
[27] M. Danks,et al. New therapeutic targets for the treatment of high‐risk neuroblastoma , 2009, Journal of cellular biochemistry.
[28] Andrew J. Bannister,et al. Unsafe SETs: histone lysine methyltransferases and cancer. , 2002, Trends in biochemical sciences.
[29] Bin Tean Teh,et al. Somatic mutations of the histone H3K27 demethylase, UTX, in human cancer , 2009, Nature Genetics.
[30] A. Kaneda,et al. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. , 2005, Cancer research.
[31] Barbara Hero,et al. Neuroblastoma: biology and molecular and chromosomal pathology. , 2003, The Lancet. Oncology.
[32] Hengbin Wang,et al. Purification and Functional Characterization of SET8, a Nucleosomal Histone H4-Lysine 20-Specific Methyltransferase , 2002, Current Biology.
[33] Xiaobo Xia,et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. , 2008, Cancer cell.
[34] Tony Kouzarides,et al. Spatial Distribution of Di- and Tri-methyl Lysine 36 of Histone H3 at Active Genes* , 2005, Journal of Biological Chemistry.
[35] Brian J. Stevenson,et al. Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line , 2009, Proceedings of the National Academy of Sciences.
[36] C. Allis,et al. PHD fingers in human diseases: disorders arising from misinterpreting epigenetic marks. , 2008, Mutation research.
[37] L. Mahadevan,et al. Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation , 2007, The EMBO journal.
[38] Paul Tempst,et al. PR-Set7 is a nucleosome-specific methyltransferase that modifies lysine 20 of histone H4 and is associated with silent chromatin. , 2002, Molecular cell.
[39] P. Grant,et al. Set2 Is a Nucleosomal Histone H3-Selective Methyltransferase That Mediates Transcriptional Repression , 2002, Molecular and Cellular Biology.
[40] D. Geerts,et al. The role of the MEIS homeobox genes in neuroblastoma. , 2003, Cancer letters.